Novel BTK Inhibitor Looks Good for Sjogren's Syndrome

(MedPage Today) -- PHILADELPHIA -- Remibrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, appeared effective in reducing signs of Sjogren's syndrome in a randomized, placebo-controlled trial. Scores on the EULAR Sjogren's...
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news